NDA 021212 · Pfizer
Caverject Impulse
Alprostadil · Injection · Prostaglandin Analog; Prostaglandin E1 Agonist
Last checked: Nov 20, 2026Latest source record: Dec 23, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2002
Jun 11, 2002
Approved uses
1
Original approval plus efficacy supplements
Registered trials
145
40 Phase 3, 8 recruiting
FAERS reports
1,749
1,471 serious, 221 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Feb 29, 2024.
CAVERJECT IMPULSE is a prostaglandin E1 agonist indicated • For the treatment of erectile dysfunction ( 1.1 ) • As an adjunct to other diagnostic tests in the diagnosis of erectile dysfunction ( 1.2 ). 1.1 Erectile Dysfunction CAVERJECT IMPULSE is indicated for the treatment of erectile dysfunction. 1.2 Diagnostic Test CAVERJECT IMPULSE is indicated as an adjunct to other diagnostic tests in the diagnosis of erectile dysfunction.
Mechanism: Alprostadil induces erection by relaxation of trabecular smooth muscle and by dilation of cavernosal arteries. This leads to expansion of lacunar spaces and entrapment of blood by compressing the venules against the tunica albuginea, a process referred to as the corporal veno-occlusive mechanism.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
2 products under this application
- CAVERJECT IMPULSE · ALPROSTADIL 0.01MG/VIAL · INJECTABLE, INJECTION · Prescription
- CAVERJECT IMPULSE · ALPROSTADIL 0.02MG/VIAL · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Alprostadil" as an intervention, any sponsor and status, largest first.
- Safety/Efficacy Study Comparing the Misoprostol Vaginal Insert to Cervidil for Cervical Ripening and Induction of LaborPivotal-lookingCompleted
Ferring PharmaceuticalsIndustry
NCT00308711 · 1,308 participants · Start Apr 2006 · Primary completion Aug 2007
Drug: Misoprostol vaginal insert 100 mcg; Misoprostol vaginal insert 50 mcg and 1 more · For: Cervical Ripening; Labor, Induced
Sites: Birmingham, Alabama; Mesa, Arizona; Phoenix, Arizona · 52 sites in all
- Study on the Efficacy of Alprostadil Injection in Patients With Acute Ischemic StrokePivotal-lookingStatus unknown
The First Hospital of Jilin UniversityAcademic, hospital or other
NCT03252626 · 950 participants (planned) · Start Apr 18, 2024 · Primary completion Dec 31, 2024
Drug: Alprostadil; Normal saline · For: Stroke
- Evaluation of Clinical Equivalence Between Two Lubiprostone Products in the Treatment of Chronic Idiopathic ConstipationPivotal-lookingCompleted
Dr. Reddy's Laboratories Limited, IndiaIndustry
NCT01674530 · 909 participants · Start Oct 2012 · Primary completion Jan 2014
Drug: Lubiprostone; Lubiprostone and 1 more · For: Chronic Idiopathic Constipation
Sites: Birmingham, Alabama; Dothan, Alabama; Huntsville, Alabama · 93 sites in all
- Alprostadil in Peripheral Arterial Occlusive Disease (PAOD) Stage IVPivotal-lookingCompleted
NCT00596752 · 840 participants · Start Mar 2004 · Primary completion May 2013
Drug: Alprostadil · For: Peripheral Arterial Occlusive Disease
Sites: Pilsen, Czechia; Ústí nad Labem, Czechia; Karlsbad, Germany · 78 sites in all
- Evaluation of Clinical Equivalence Between Two Lubiprostone ProductsPivotal-lookingCompleted
Anchen Pharmaceuticals, IncIndustry
NCT01372423 · 808 participants · Start May 2011 · Primary completion Jun 2012
Drug: Lubiprostone; Placebo · For: Chronic Idiopathic Constipation
Sites: Dothan, Alabama; Huntsville, Alabama; Mobile, Alabama · 79 sites in all
- Labor Induction and Maternal BMI, Comparison of Different Pre-induction Cervical Ripening MethodsPivotal-lookingStatus unknown
Hillel Yaffe Medical CenterGovernment (non-federal)
NCT02223949 · 624 participants (planned) · Start Oct 2014 · Primary completion Oct 2016
Drug: PGE1 tablet · For: Obesity; Labor Complications
Sites: Hadera, Israel
- Lubiprostone in Children With Functional ConstipationPivotal-lookingCompleted
Sucampo Pharma Americas, LLCIndustry
NCT02042183 · 606 participants · Start Dec 13, 2013 · Primary completion Jul 27, 2016
Drug: Lubiprostone; Placebo · For: Constipation - Functional
Sites: Birmingham, Alabama; Mobile, Alabama; Phoenix, Arizona · 117 sites in all
- ALP-1 Continuous Intravenous Infusion to Maintain Clinical Stability in Advanced Heart FailurePivotal-lookingNot yet recruiting
Biopeutics Co., LtdIndustry
NCT00610051 · 600 participants (planned) · Start Oct 2026 · Primary completion Nov 2029
Drug: Alprostadil · For: End Stage Cardiac Failure; HFrEF - Heart Failure With Reduced Ejection Fraction; NYHF Class III-IV
Sites: Vienna, Austria
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective205
- off label use129
- haemoglobin decreased82
- lymphocyte count decreased79
- diarrhoea69
- pyrexia69
- cardiac failure62
- blood urea increased59
- condition aggravated55
- anaemia54
- blood glucose increased54
- neutrophil count increased54
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 46 |
| 2005 | 60 |
| 2006 | 71 |
| 2007 | 40 |
| 2008 | 56 |
| 2009 | 34 |
| 2010 | 65 |
| 2011 | 104 |
| 2012 | 73 |
| 2013 | 35 |
| 2014 | 21 |
| 2015 | 81 |
| 2016 | 118 |
| 2017 | 170 |
| 2018 | 107 |
| 2019 | 122 |
| 2020 | 98 |
| 2021 | 97 |
| 2022 | 81 |
| 2023 | 65 |
| 2024 | 81 |
| 2025 | 64 |
| 2026 | 59 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Erectile dysfunction.
Khera M, Goldstein I · BMJ Clin Evid 2011 · Systematic Review
- Alprostadil for hypertensive nephropathy: A systematic review and meta-analysis of randomized controlled trials.
Fu H, Hou W, Zhang Y, et al. · PLoS One 2022 · Meta-Analysis, Systematic Review
- The effect of topical and intraurethral alprostadil on erectile function: A systematic review and meta-analysis.
Papadopoulos I, Tishukov M, Sokolakis I, et al. · Andrology 2025 · Systematic Review, Meta-Analysis
- Shenkang injection combined with alprostadil for chronic renal failure: A systematic review and meta-analysis.
Xie F, Zhang T, Zhang P, et al. · Front Med (Lausanne) 2023 · Systematic Review
- Efficacy of Alprostadil in Preventing Contrast-Induced Nephropathy: A Systematic Review and Meta-Analysis.
Xu H, Wang H, Zhang C, et al. · Angiology 2021 · Meta-Analysis, Systematic Review
- Efficacy of alprostadil for preventing of contrast-induced nephropathy: A meta-analysis.
Zhang JZ, Kang XJ, Gao Y, et al. · Sci Rep 2017 · Meta-Analysis, Research Support, Non-U.S. Gov't
Sponsor: Pfizer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.